

Katharina Prieske

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4428616/publications.pdf>

Version: 2024-02-01

29
papers

468
citations

759233

12
h-index

713466

21
g-index

31
all docs

31
docs citations

31
times ranked

825
citing authors

#	ARTICLE	IF	CITATIONS
1	Prevalence of deleterious germline variants in risk genes including BRCA1/2 in consecutive ovarian cancer patients (AGO-TR-1). PLoS ONE, 2017, 12, e0186043.	2.5	105
2	Patterns of distant metastases in vulvar cancer. Gynecologic Oncology, 2016, 142, 427-434.	1.4	47
3	The Risk of Contralateral Non-sentinel Metastasis in Patients with Primary Vulvar Cancer and Unilaterally Positive Sentinel Node. Annals of Surgical Oncology, 2016, 23, 2508-2514.	1.5	37
4	Deleterious somatic variants in 473 consecutive individuals with ovarian cancer: results of the observational AGO-TR1 study (NCT02222883). Journal of Medical Genetics, 2019, 56, 574-580.	3.2	34
5	<i>BRCA1</i> Promoter Methylation and Clinical Outcomes in Ovarian Cancer: An Individual Patient Data Meta-Analysis. Journal of the National Cancer Institute, 2020, 112, 1190-1203.	6.3	32
6	Pre-Analytical and Analytical Variables of Label-Independent Enrichment and Automated Detection of Circulating Tumor Cells in Cancer Patients. Cancers, 2020, 12, 442.	3.7	28
7	Genomic characterization of vulvar squamous cell carcinoma. Gynecologic Oncology, 2020, 158, 547-554.	1.4	21
8	p53 and p16 expression profiles in vulvar cancer: a translational analysis by the Arbeitsgemeinschaft Gynäkologische Onkologie Chemo and Radiotherapy in Epithelial Vulvar Cancer study group. American Journal of Obstetrics and Gynecology, 2021, 224, 595.e11-595.e11.	1.3	21
9	Sexual activity and function after surgical treatment in patients with (pre)invasive vulvar lesions. Supportive Care in Cancer, 2016, 24, 419-428.	2.2	20
10	Clonal Hematopoiesis-Associated Gene Mutations in a Clinical Cohort of 448 Patients With Ovarian Cancer. Journal of the National Cancer Institute, 2022, 114, 565-570.	6.3	17
11	Beyond Bevacizumab: An Outlook to New Anti-Angiogenics for the Treatment of Ovarian Cancer. Frontiers in Oncology, 2015, 5, 211.	2.8	16
12	Predicting the course of disease in recurrent vulvar cancer – A subset analysis of the AGO-CaRE-1 study. Gynecologic Oncology, 2019, 154, 571-576.	1.4	15
13	Adjuvant radiotherapy and local recurrence in vulvar cancer – a subset analysis of the AGO-CaRE-1 study. Gynecologic Oncology, 2022, 164, 68-75.	1.4	12
14	Course of cervical intraepithelial neoplasia diagnosed during pregnancy. Archives of Gynecology and Obstetrics, 2020, 301, 1503-1512.	1.7	11
15	Participation of elderly gynecological cancer patients in clinical trials. Archives of Gynecology and Obstetrics, 2018, 298, 797-804.	1.7	9
16	Ovarian Cancer-Specific <i>BRCA</i> -like Copy-Number Aberration Classifiers Detect Mutations Associated with Homologous Recombination Deficiency in the AGO-TR1 Trial. Clinical Cancer Research, 2021, 27, 6559-6569.	7.0	9
17	Superficially invasive stage IA vulvar squamous cell carcinoma – therapy and prognosis. International Journal of Gynecological Cancer, 2019, 29, 466-473.	2.5	8
18	<i>BRCA1</i> promoter hypermethylation on circulating tumor DNA correlates with improved survival of patients with ovarian cancer. Molecular Oncology, 2021, 15, 3615-3625.	4.6	8

#	ARTICLE	IF	CITATIONS
19	Age, treatment and prognosis of patients with squamous cell vulvar cancer (VSCC) - analysis of the AGO-CaRE-1 study. <i>Gynecologic Oncology</i> , 2021, 161, 442-448.	1.4	4
20	Role of Pelvic Lymph Node Resection in Vulvar Squamous Cell Cancer: A Subset Analysis of the AGO-CaRE-1 Study. <i>Annals of Surgical Oncology</i> , 2021, 28, 6696-6704.	1.5	3
21	Transcriptome Analysis in Vulvar Squamous Cell Cancer. <i>Cancers</i> , 2021, 13, 6372.	3.7	3
22	Cerebral metastasis in recurrent squamous cell carcinoma of the vulva: case report and review of the literature. <i>Archives of Gynecology and Obstetrics</i> , 2020, 301, 327-332.	1.7	2
23	Incidence of germline mutations in risk genes including <i>BRCA1/2</i> in consecutive ovarian cancer (OC) patients (AGO TR-1).. <i>Journal of Clinical Oncology</i> , 2016, 34, 5538-5538.	1.6	2
24	Pelvic Lymphadenectomy in Vulvar Cancer – Does it make sense?. <i>Geburtshilfe Und Frauenheilkunde</i> , 2020, 80, 1221-1228.	1.8	2
25	Comparison of PapilloCheck and linear array to detect and differentiate human papillomaviruses in cervical and tonsillar smears from females with cervical intraepithelial lesions. <i>European Journal of Microbiology and Immunology</i> , 2018, 8, 107-111.	2.8	1
26	The risk of contralateral non sentinel metastasis in patients with primary vulvar cancer and unilaterally positive sentinel node.. <i>Journal of Clinical Oncology</i> , 2015, 33, e16600-e16600.	1.6	1
27	Reply to letter to the editor. <i>Archives of Gynecology and Obstetrics</i> , 2019, 300, 487-487.	1.7	0
28	Evaluation of treatment patterns and prognosis in correlation with age in patients with vulvar cancer: A subset analysis of the AGO-CaRE-1 study.. <i>Journal of Clinical Oncology</i> , 2020, 38, 6090-6090.	1.6	0
29	Risk for Pelvic Metastasis and Role of Pelvic Lymphadenectomy in Node-Positive Vulvar Cancer-Results from the AGO-VOP.2 QS Vulva Study. <i>Cancers</i> , 2022, 14, 418.	3.7	0